PSQ Holdings, Inc. filed a Form 8-K on November 13, 2026, disclosing that the New York Stock Exchange notified the company on November 9, 2026 that it had commenced proceedings to delist the company's Class A common stock and public warrants, with trading in …
Aptera Motors Corp. filed a Form 8-K on November 13, 2026, disclosing financial information and operating metrics for its fiscal quarter ended September 30, 2026, via an attached press release.
NextNRG, Inc. filed a Form 8-K on November 13, 2026, disclosing that trading in its common stock on Nasdaq was suspended at the open of trading on November 12, 2026, following a Nasdaq Hearings Panel decision to deny the company's request to continue its …
Creative Medical Technology Holdings, Inc. filed a Form 8-K on November 13, 2026, disclosing that it received a Nasdaq deficiency notice on November 10, 2026, for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
Skyworks Solutions, Inc. filed a Form 8-K/A on November 13, 2026, amending its October 5, 2026 current report to disclose committee assignments for two recently appointed directors, effective November 11, 2026.
BWX Technologies, Inc. filed a Form 8-K with the SEC on November 13, 2026, disclosing the issuance of $500,000,000 in new senior notes and the satisfaction and discharge of two existing note series following a completed tender offer and consent solicitation.
Ethan Allen Interiors Inc. filed a Form 8-K on November 13, 2026, disclosing that M. Farooq Kathwari resigned as President and Chief Executive Officer on November 9, 2026, that Stefanie T. Ward was appointed Interim CEO effective the same date, and that director Douglas …
Science Applications International Corporation filed a Form 8-K on November 13, 2026, disclosing the closing of a $500 million private offering of 6.750% Senior Notes due 2034 and the use of proceeds to redeem its outstanding 4.875% Senior Notes due 2028.
Incyte Corporation filed a current report on November 13, 2026, disclosing its decision not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667 in combination with bevacizumab as first-line maintenance therapy in ovarian cancer patients.
Greenland Technologies Holding Corporation filed a Form 8-K on November 13, 2026, disclosing that it received a Nasdaq minimum bid price deficiency notification on November 10, 2026, after its Class A ordinary shares closed below $1.00 per share for 30 consecutive business days.